Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial
- 14 March 2019
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (7) , 1642-1651
Abstract
Aim: To evaluate the efficacy and safety of colchicine for improving metabolic and inflammatory outcomes in people with obesity and metabolic syndrome (MetS). Materials and methods: Adults with obesity and MetS, but who did not have diabetes, were randomized to colchicine 0.6 mg or placebo capsules twice daily for 3 months. The primary outcome was change in insulin sensitivity (S I ) as estimated by insulin‐modified frequently sampled intravenous glucose tolerance tests. Secondary outcomes included changes in other metabolic variables and inflammatory markers. Results: Of 40 participants randomized (21 colchicine, 19 placebo), 37 completed the trial. Compared with placebo, colchicine significantly reduced C‐reactive protein ( P P P P I was not significantly different between colchicine and placebo arms (difference: +0.21 × 10 −5 ; CI −1.70 to +2.13 × 10 −5 min −1 mU −1 mL; P = 0.82). However, changes in some secondary outcomes, including homeostatic model assessment of insulin resistance ( P = 0.0499), fasting insulin ( P = 0.07) and glucose effectiveness ( P = 0.08), suggested metabolic improvements in the colchicine versus placebo group. Adverse events were generally mild and similar in both groups. Conclusions: This pilot study found colchicine significantly improved obesity‐associated inflammatory variables and showed a good safety profile among adults with obesity and MetS who did not have diabetes. These results suggest a larger, adequately powered study should be conducted to determine whether colchicine improves insulin resistance and other measures of metabolic health in at‐risk individuals.Keywords
Funding Information
- National Institutes of Health (1ZIAHD000641)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIAHD00641)
This publication has 46 references indexed in Scilit:
- Prediabetes: a high-risk state for diabetes developmentThe Lancet, 2012
- Inflammasome is a central player in the induction of obesity and insulin resistanceProceedings of the National Academy of Sciences, 2011
- Elimination of the NLRP3-ASC Inflammasome Protects against Chronic Obesity-Induced Pancreatic DamageEndocrinology, 2011
- Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndromeFertility and Sterility, 2011
- Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trialThe American Journal of Clinical Nutrition, 2011
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistanceNature Medicine, 2011
- TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2011
- The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin SensitivityCell Metabolism, 2010
- A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in WomenDiabetes Care, 2009
- Inflammation and metabolic disordersNature, 2006